Therapeutic Treatment Approaches Post-Myocardial Infarction: A Bias Toward Formyl Peptide Receptor Agonists
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
First Author:
Corresponding Author:
References
1.
Qin C, May L, Li R, Cao N, Rosli S, Deo M
. Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nat Commun. 2017; 8:14232.
PMC: 5309721.
DOI: 10.1038/ncomms14232.
View
2.
He H, Ye R
. The Formyl Peptide Receptors: Diversity of Ligands and Mechanism for Recognition. Molecules. 2017; 22(3).
PMC: 6155412.
DOI: 10.3390/molecules22030455.
View
3.
Jong R, Leoni G, Drechsler M, Soehnlein O
. The advantageous role of annexin A1 in cardiovascular disease. Cell Adh Migr. 2016; 11(3):261-274.
PMC: 5479459.
DOI: 10.1080/19336918.2016.1259059.
View
4.
Dick S, Macklin J, Nejat S, Momen A, Clemente-Casares X, Althagafi M
. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. Nat Immunol. 2018; 20(1):29-39.
PMC: 6565365.
DOI: 10.1038/s41590-018-0272-2.
View
5.
Garcia R, Ito B, Lupisella J, Carson N, Hsu M, Fernando G
. Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment. JACC Basic Transl Sci. 2020; 4(8):905-920.
PMC: 6939031.
DOI: 10.1016/j.jacbts.2019.07.005.
View